BRCA2 and ovarian carcinoma: In the province of Quebec, Canada, after rigorous evaluation of the evidence, the National Institute of Excellence in Health and Social Services (INESSS) recommended that the Ministry of Health and Social Services (MSSS) include genetic testing for the detection of BRCA1 and BRCA2 pathogenic variants for breast and ovarian cancer in the medical biology procedures directory [24].